NCT04535063View on ClinicalTrials.gov

Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia

PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

April 18, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

February 25, 2021

Conditions

Covid19 Pneumonia

Interventions

BIOLOGICAL

COVID19 convalescent plasma infusion

intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)

Trial Locations (1)

1425

Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires

All Listed Sponsors

lead

Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno

OTHER

NCT04535063 - Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter